Amylyx Pharmaceuticals (AMLX) News Today $5.31 -0.05 (-0.93%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$5.20 -0.11 (-2.17%) As of 05/23/2025 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AMLX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period OMERS ADMINISTRATION Corp Purchases New Shares in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)OMERS ADMINISTRATION Corp bought a new stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 66,000 shares of the companyMay 22 at 4:24 AM | marketbeat.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Consensus Rating of "Buy" from AnalystsAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) has earned an average rating of "Buy" from the eight research firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, five have issued a buy recommendation aMay 22 at 1:30 AM | marketbeat.comDimensional Fund Advisors LP Acquires Shares of 54,114 Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)Dimensional Fund Advisors LP purchased a new position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 54,114 shares of the company's sMay 20, 2025 | marketbeat.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Consensus Rating of "Buy" from BrokeragesMay 20, 2025 | americanbankingnews.comJacobs Levy Equity Management Inc. Has $1.19 Million Stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)Jacobs Levy Equity Management Inc. trimmed its position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 34.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 314,939 shares of theMay 19, 2025 | marketbeat.comAmylyx Pharmaceuticals (NASDAQ:AMLX) versus Perrigo (NYSE:PRGO) Head to Head ComparisonMay 18, 2025 | americanbankingnews.comAmylyx Pharmaceuticals (NASDAQ:AMLX) Price Target Raised to $8.00May 17, 2025 | americanbankingnews.comJane Street Group LLC Boosts Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)Jane Street Group LLC lifted its position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 122.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 765,475 shares of the company'sMay 16, 2025 | marketbeat.comOrbimed Advisors LLC Takes Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)Orbimed Advisors LLC purchased a new position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 348,000 shares of the company's stock, valuedMay 15, 2025 | marketbeat.comCubist Systematic Strategies LLC Purchases 423,316 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)Cubist Systematic Strategies LLC boosted its position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 862.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 472,397 shares of the company'sMay 15, 2025 | marketbeat.comAmylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram SyndromeMay 12, 2025 | businesswire.comAmylyx Pharmaceuticals (NASDAQ:AMLX) Price Target Raised to $16.00 at HC WainwrightHC Wainwright increased their target price on Amylyx Pharmaceuticals from $12.00 to $16.00 and gave the company a "buy" rating in a research report on Friday.May 11, 2025 | marketbeat.comLeerink Partnrs Has Positive Estimate for AMLX Q1 EarningsAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) - Stock analysts at Leerink Partnrs raised their Q1 2025 EPS estimates for shares of Amylyx Pharmaceuticals in a report issued on Tuesday, May 6th. Leerink Partnrs analyst M. Goodman now forecasts that the company will earn ($0.47) per sharMay 11, 2025 | marketbeat.comAmylyx Pharmaceuticals, Inc. (AMLX) Q1 2025 Earnings Call TranscriptMay 10, 2025 | seekingalpha.comHere's Why We're A Bit Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn SituationMay 10, 2025 | finance.yahoo.comAmylyx Pharmaceuticals (NASDAQ:AMLX) Rating Increased to Strong-Buy at Leerink PartnrsLeerink Partnrs upgraded shares of Amylyx Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Tuesday.May 10, 2025 | marketbeat.comAmylyx Pharmaceuticals to Participate in Upcoming May Investor ConferencesMay 9, 2025 | nasdaq.comAmylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded at Leerink PartnersLeerink Partners raised Amylyx Pharmaceuticals from a "market perform" rating to an "outperform" rating and raised their price objective for the company from $4.00 to $10.00 in a report on Wednesday.May 9, 2025 | marketbeat.comAmylyx Pharmaceuticals Inc (AMLX) Q1 2025 Earnings Call Highlights: Strategic Advances and ...May 9, 2025 | finance.yahoo.comAlyeska Investment Group L.P. Has $3.11 Million Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)Alyeska Investment Group L.P. reduced its holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 59.3% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 823,420 shares of the company's stock after selling 1,200,000 shares during theMay 9, 2025 | marketbeat.comAmylyx Pharmaceuticals Reports First Quarter 2025 Financial ResultsMay 8, 2025 | businesswire.comThis Biotech Found Mid-Week Success Following Analyst UpgradeMay 7, 2025 | msn.comLeerink Partners Upgrades Amylyx Pharmaceuticals (AMLX)May 7, 2025 | msn.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Sold by JPMorgan Chase & Co.JPMorgan Chase & Co. reduced its stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 60.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 55,606 shares of the company's stock after selling 8May 6, 2025 | marketbeat.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Sold by 683 Capital Management LLC683 Capital Management LLC lowered its stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 3.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,930,000 shares of the company's stock after selliMay 4, 2025 | marketbeat.comBoxer Capital Management LLC Invests $6.62 Million in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)Boxer Capital Management LLC purchased a new stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 1,750,000 shares of the company's stock, valued atMay 4, 2025 | marketbeat.comMarshall Wace LLP Sells 99,308 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)Marshall Wace LLP trimmed its holdings in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 35.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 184,678 shares of the company's stock afterMay 4, 2025 | marketbeat.comAmylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025May 3, 2025 | seekingalpha.comAmylyx Pharmaceuticals (AMLX) Expected to Announce Earnings on ThursdayAmylyx Pharmaceuticals (NASDAQ:AMLX) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-amylyx-pharmaceuticals-inc-stock/)May 3, 2025 | marketbeat.comAmylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric HypoglycemiaApril 30, 2025 | finance.yahoo.comNantahala Capital Management LLC Acquires 47,589 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)Nantahala Capital Management LLC grew its holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 3.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,452,153 shares of the company's stockApril 30, 2025 | marketbeat.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Purchased by Renaissance Technologies LLCRenaissance Technologies LLC raised its position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 70.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 464,400 shares of the compApril 29, 2025 | marketbeat.comJump Financial LLC Invests $394,000 in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)Jump Financial LLC bought a new stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 104,342 shares of the company's stocApril 28, 2025 | marketbeat.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Rating of "Moderate Buy" from BrokeragesShares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the seven brokerages that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating, four have issuedApril 27, 2025 | marketbeat.comAlpha Wave Global LP Has $562,000 Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)Alpha Wave Global LP reduced its position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 77.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 148,627 shares of the company's stock after selling 520,860April 20, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for AMLX Q1 Earnings?Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) - Research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Amylyx Pharmaceuticals in a report issued on Sunday, April 13th. Leerink Partnrs analyst M. Goodman anticipates that the company will earn ($0.52) per share for tApril 18, 2025 | marketbeat.comKuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law FirmApril 16, 2025 | gurufocus.comKuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law FirmApril 16, 2025 | globenewswire.comIs Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) the Best Biotech Penny Stock to Buy According to Hedge Funds?April 16, 2025 | msn.comExodusPoint Capital Management LP Acquires New Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)ExodusPoint Capital Management LP bought a new position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 106,237 shares of the company's stock, valued at approximateApril 15, 2025 | marketbeat.comWellington Management Group LLP Makes New $793,000 Investment in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)Wellington Management Group LLP purchased a new stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 209,708 shares of the company's stock, valued at approximately $793,000. WApril 15, 2025 | marketbeat.comAmylyx doses first participant in LUMINA trialApril 9, 2025 | markets.businessinsider.comAmylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded to "Outperform" at MizuhoMizuho upgraded shares of Amylyx Pharmaceuticals from a "neutral" rating to an "outperform" rating and set a $7.00 price objective on the stock in a research note on Monday.April 9, 2025 | marketbeat.comAmylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral SclerosisApril 9, 2025 | businesswire.comAmylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral SclerosisApril 9, 2025 | businesswire.comAmylyx upgraded to Outperform from Neutral at MizuhoApril 8, 2025 | markets.businessinsider.comPositive Report for Amylyx Pharmaceuticals Inc (AMLX) from Mizuho SecuritiesApril 8, 2025 | markets.businessinsider.comMizuho Upgrades Amylyx Pharmaceuticals (AMLX)April 8, 2025 | msn.comAmylyx upgraded at Mizuho on potential of lead assetApril 7, 2025 | msn.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CFO James M. Frates Sells 10,896 SharesAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) CFO James M. Frates sold 10,896 shares of the firm's stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $3.47, for a total transaction of $37,809.12. Following the transaction, the chief financial officer now directly owns 290,988 shares in the company, valued at $1,009,728.36. This represents a 3.61 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.April 4, 2025 | marketbeat.com Get Amylyx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter. Email Address AMLX Media Mentions By Week AMLX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AMLX News Sentiment▼0.730.75▲Average Medical News Sentiment AMLX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AMLX Articles This Week▼63▲AMLX Articles Average Week Get Amylyx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CG Oncology News Today Tarsus Pharmaceuticals News Today Galapagos News Today Apogee Therapeutics News Today Recursion Pharmaceuticals News Today Twist Bioscience News Today Beam Therapeutics News Today Arcutis Biotherapeutics News Today Agios Pharmaceuticals News Today Schrödinger News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AMLX) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | SponsoredMemorial Day Sale! Save 85% on Weiss Crypto Investor!President Trump just made his first big crypto move … Announcing the creation of a national strategic reser...Weiss Ratings | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amylyx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AMLX Stock Free AMLX Stock Alerts